Publications by authors named "Pippa Loupe"

Claim this Profile
A
An Evaluation of the Subcutaneous Depot Release of TV-46000, A Novel Long-Acting Injectable (LAI) Formulation of Risperidone, Under Extreme Conditions in Dogs, Minipigs and Humans.
Lilach Steiner, David Bibi, Avia Merenlender Wagner, Pavel Farkas, Safra Rudnick-Glick, Pippa Loupe

Pharmaceutics· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Bioequivalence Comparison Between the Once-Daily Extended-Release Tablet and the Twice-Daily Tablet Formulations of Deutetrabenazine at Steady State.
Eva-Maria Sunzel, Laura Rabinovich-Guilatt, Malini Iyengar, Debra Ruffo, Nagnath G Birajdar, Pippa Loupe

Clin Pharmacol Drug Dev· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study.
Ralf Reilmann, Karen E Anderson, Andrew Feigin, Sarah J Tabrizi, Blair R Leavitt, Pippa Loupe

Lancet Neurol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Deutetrabenazine's Potential to Delay Cardiac Repolarization Using Concentration-QTc Analysis.
Frank Schneider, Borje Darpo, Pippa S Loupe, Hongqi Xue, Helena Knebel

Clin Pharmacol Drug Dev· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetic Modeling and Simulation of TV-46000: A Long-Acting Injectable Formulation of Risperidone.
Itay Perlstein, Avia Merenlender Wagner, Roberto Gomeni, Michael Lamson, Eran Harary, Pippa Loupe

Clin Pharmacol Drug Dev· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Pharmacokinetic Bioequivalence Study of Fremanezumab Administered Subcutaneously Using an Autoinjector and a Prefilled Syringe.
Irina Cherniakov, Orit Cohen-Barak, Ryan Tiver, Michael Gillespie, Yoel Kessler, Pippa S Loupe

Clin Pharmacol Drug Dev· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose selection for fremanezumab (AJOVY) phase 3 pediatric migraine studies using pharmacokinetic data from a pediatric phase 1 study and a population pharmacokinetic modeling and simulation approach.
Orit Cohen-Barak, Andrijana Radivojevic, Aksana Jones, Jill Fiedler-Kelly, Michael Gillespie, Pippa Loupe

Cephalalgia· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
On crushing of deutetrabenazine tablets.
Helena Knebel, Jessica Alexander, Amanda Wilhelm, Pippa Loupe, Frank Schneider

Am J Health Syst Pharm· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of Deutetrabenazine and Tetrabenazine: Dose Proportionality and Food Effect.
Frank Schneider, David Stamler, Margaret Bradbury, Pippa S Loupe, Edward Hellriegel

Clin Pharmacol Drug Dev· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effect of CYP3A Induction and Inhibition on the Pharmacokinetics of Laquinimod, a Novel Neuroimmunomodulator.
Anna Elgart, David J Greenblatt, Pippa S Loupe, Arik A Zur, Sivan Weiss

Clin Pharmacol Drug Dev· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic and Metabolic Profile of Deutetrabenazine (TEV-50717) Compared With Tetrabenazine in Healthy Volunteers.
Frank Schneider, Margaret Bradbury, Thomas A Baillie, David Stamler, Edward Hellriegel, Pippa S Loupe

Clin Transl Sci· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantification of Motor Function in Huntington Disease Patients Using Wearable Sensor Devices.
Mark Forrest Gordon, Igor D Grachev, Itzik Mazeh, Yonatan Dolan, Ralf Reilmann, Pippa S Loupe

Digit Biomark· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physicochemical and Biological Examination of Two Glatiramer Acetate Products.
Arthur Komlosh, Vera Weinstein, Pippa Loupe, Tal Hasson, Bracha Timan

Biomedicines· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effect of Beginning Treatment With Fremanezumab on Headache and Associated Symptoms in the Randomized Phase 2 Study of High Frequency Episodic Migraine: Post-Hoc Analyses on the First 3 Weeks of Treatment.
Stephen D Silberstein, Alan M Rapoport, Pippa S Loupe, Ernesto Aycardi, Mirna McDonald

Headache· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trials.
Rashmi B Halker Singh, Ernesto Aycardi, Marcelo E Bigal, Pippa S Loupe, Mirna McDonald

Cephalalgia· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to the Letter-to-the Editor by Cohen et al. concerning our eNeurologicalSci article, Melamed-Gal, et al. Physicochemical, biological, functional and toxicological characterization of the European follow-on glatiramer acetate product as compared with Copaxone. eNeurologicalSci 2018;12:19-30.https://doi.org/10.1016/j.ensci.2018.05.006.
Sigal Melamed-Gal, Pippa Loupe, Bracha Timan, Vera Weinstein, Sarah Kolitz

eNeurologicalSci· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects.
Orit Cohen-Barak, Sivan Weiss, Michele Rasamoelisolo, Nicola Faulhaber, Paul P Yeung, Pippa S Loupe

Cephalalgia· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjects.
Frank Schneider, Lavi Erisson, Hooman Beygi, Margaret Bradbury, Orit Cohen-Barak, Pippa S Loupe

Br J Clin Pharmacol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fremanezumab for preventive treatment of migraine: Functional status on headache-free days.
Juliana VanderPluym, David W Dodick, Richard B Lipton, Yuju Ma, Pippa S Loupe

Neurology· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Compositional differences between Copaxone and Glatopa are reflected in altered immunomodulation ex vivo in a mouse model.
Iris Grossman, Sarah Kolitz, Arthur Komlosh, Benjamin Zeskind, Vera Weinstein, Pippa Loupe

Ann N Y Acad Sci· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacogenomics strategies to optimize treatments for multiple sclerosis: Insights from clinical research.
Iris Grossman, Volker Knappertz, Daphna Laifenfeld, Colin Ross, Ben Zeskind, Pippa Loupe

Prog Neurobiol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Placebo-controlled evaluation of a bioengineered, cocaine-metabolizing fusion protein, TV-1380 (AlbuBChE), in the treatment of cocaine dependence.
Yossi Gilgun-Sherki, Rom E Eliaz, David J McCann, Pippa S Loupe, Eli Eyal

Drug Alcohol Depend· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TEV-48125 for the preventive treatment of chronic migraine: Efficacy at early time points.
Marcelo E Bigal, David W Dodick, Abouch V Krymchantowski, Juliana H VanderPluym, Stewart J Tepper, Pippa S Loupe

Neurology· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells.
Lucianne Dobson, Ulrike Träger, Ruth Farmer, Liat Hayardeny, Pippa Loupe

J Neurochem· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.
Marcelo E Bigal, David W Dodick, Alan M Rapoport, Stephen D Silberstein, Yuju Ma, Pippa S Loupe

Lancet Neurol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis